76 Multiple Myeloma Clinical Trials in New York, NY (2026)

Q: How do I join a clinical trial in New York?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the New York research site will contact you.

Recruiting Multiple Myeloma Studies in New York

NCT07656584Recruiting

Implementation of Communication Disability Collection and Accommodations in Primary Care Settings

This multi-methods-multi-site study aims to adapt and evaluate the effects of an implementation support package of strategies to assist primary care clinics in documenting patients' communication disa...

New York, NYNA126,870 participantsNYU Langone Health

View Study Details

NCT02735707Recruiting

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to impro...

New York, NYPHASE320,000 participantsUMC Utrecht

View Study Details

NCT05584488Recruiting

Allergy and Immunology Natural History Study

This protocol is a natural history study designed to evaluate subjects (and some family members) with suspected or identified genetic diseases of allergic inflammation or Immune Dysregulation. Patient...

New York, NY10,000 participantsColumbia University

View Study Details

NCT05968573Recruiting

Persuasive Health Communication Intervention for HIV/HCV

A major impediment to emergency department (ED)-based HIV/HCV screening success is that often ED patients at risk for, or later diagnosed with, HIV and HCV decline testing. In this R01 project, the re...

New York, NYNA2,000 participantsUniversity of South Florida

View Study Details

NCT05623020Recruiting

A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

Elranatamab is a bispecific antibody: binding of elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity. The main purpose of the ...

New York, NYPHASE31,116 participantsPfizer

View Study Details

NCT05020236Recruiting

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

The purpose of this clinical trial is to (1) learn whether the BCMA-CD3 bispecific antibody elranatamab can provide more benefit to people with multiple myeloma compared to a combination therapy inclu...

New York, NYPHASE3944 participantsPfizer

View Study Details

NCT07222761Recruiting

A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

This study is researching a drug called linvoseltamab (also called "study drug") either given alone or in combination with another anti-myeloma drug called carfilzomib, compared to several standard tr...

New York, NYPHASE3915 participantsRegeneron Pharmaceuticals

View Study Details

NCT04784364Recruiting

Biologics And Clinical Immunology Cohort at Sinai

The study team plans to establish a bioregistry of patients receiving biologic therapy as part of their standard treatment at the Mount Sinai Therapeutic Infusion Center and affiliated practices. The ...

New York, NY800 participantsIcahn School of Medicine at Mount Sinai

View Study Details

NCT07518186Recruiting

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to evaluate how well JNJ-79635322 works when compared with teclistamab....

New York, NYPHASE3700 participantsJanssen Research & Development, LLC

View Study Details

NCT07095452Recruiting

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, in...

New York, NYPHASE2660 participantsAbbVie

View Study Details

NCT04634552Recruiting

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to evaluate the efficacy and safety of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3)....

New York, NYPHASE2510 participantsJanssen Research & Development, LLC

View Study Details

NCT05438043Recruiting

A Study of Daratumumab

The purpose of this study is to provide ongoing access to study treatments for participants with multiple myeloma or smoldering multiple myeloma benefiting from treatment in certain Janssen Research a...

New York, NYPHASE3500 participantsJanssen Research & Development, LLC

View Study Details

NCT06598397Recruiting

Using Multiphase Optimization Strategy (MOST) to Optimize a Cost-effective, Sustainable and Scalable Smoking Cessation Package for Smokers in HIV Clinical Care

This study's long-term goal is to improve clinical outcomes among smokers living with HIV (SLWH) by providing smoking cessation interventions in HIV clinical care that will increase the chances of qui...

New York, NYPHASE4500 participantsNew York University

View Study Details

NCT07511621Recruiting

A Multi-Level Strategy for De-implementing Mammography Overuse Among Older Women

This project aims to advance methodological and theoretical approaches for developing, selecting, refining, and piloting a multilevel de-implementation strategy to reduce the overuse of screening mamm...

New York, NYNA500 participantsColumbia University

View Study Details

NCT05477901Recruiting

Impacts of Cash Transfers on Child Neurodevelopment (Auxilio Brasil)

This study examines the impact of Auxilio Brasil (AB), a cash transfer program to mothers of school-age children, on resource-deprived populations in Brazil and its protective effects on child neurode...

New York, NYNA450 participantsNew York State Psychiatric Institute

View Study Details

NCT06892522Recruiting

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib

New York, NYPHASE1440 participantsAbbVie

View Study Details

NCT06365060Recruiting

Screening for AL Amyloidosis in Smoldering Multiple Myeloma

In this multicenter study, we will recruit 400 patients 40 years of age or older at 15 centers with a diagnosis of smoldering multiple myeloma (SMM), a group of patients for whom standard of care is o...

New York, NY400 participantsTufts Medical Center

View Study Details

NCT06266663Recruiting

Social Determinants of Health, Medication Use, and Quality of Life in Inflammatory Bowel Disease

Optimizing health related-quality of life (HRQoL) for patients with inflammatory bowel disease (IBD), who often experience a relapsing disease course, is an essential component of care. Improving IBD ...

New York, NY400 participantsMontefiore Medical Center

View Study Details

NCT03761108Recruiting

Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma

The main purpose of this study is to learn about the safety of linvoseltamab and to find out what is the best dose of linvoseltamab to give to patients with multiple myeloma and to look for any signs ...

New York, NYPHASE1387 participantsRegeneron Pharmaceuticals

View Study Details

NCT05137054Recruiting

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

This study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multiple myeloma. Linvoseltamab has previously been studi...

New York, NYPHASE1317 participantsRegeneron Pharmaceuticals

View Study Details

NCT02343042Recruiting

Selinexor and Backbone Treatments of Multiple Myeloma Patients

This study will independently assess the efficacy and safety of 11 combination therapies in 12 arms, in dose-escalation/-evaluation and expansion phases, for the treatment of patients with relapsed/re...

New York, NYPHASE1300 participantsKaryopharm Therapeutics Inc

View Study Details

NCT05231629Recruiting

Sequential Therapy in Multiple Myeloma Guided by MRD Assessments

This research study will determine the proportion of patients with lowest minimal residual disease (MRD) response obtainable after receiving 6 cycles of study treatment. Minimal residual disease is mu...

New York, NYPHASE2300 participantsUniversity of Alabama at Birmingham

View Study Details

NCT07053436Recruiting

Horizon Two: HR NDMM (MMRC-100)

The Multiple Myeloma Research Consortium (MMRC) Horizon Two trial is a master protocol, multi-center, phase II randomized adaptive platform trial designed to efficiently evaluate multiple investigatio...

New York, NYPHASE2300 participantsMultiple Myeloma Research Consortium

View Study Details

NCT05372354Recruiting

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to assess the safety, tolerability and preliminary effectiveness of CC-92480 (BMS-986348) in novel therapeutic combinations for the treatment of Relapsed or Refractory Mul...

New York, NYPHASE1260 participantsBristol-Myers Squibb

View Study Details

NCT04973605Recruiting

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

The purpose of this study is to assess the safety, tolerability, and efficacy of sonrotoclax as monotherapy and in various combinations in patients with relapsed/refractory (R/R) multiple myeloma (MM)...

New York, NYPHASE1246 participantsBeiGene

View Study Details

NCT06685003Recruiting

Phase II: Scalable Digital Delivery of CRAFT Training for Professionals to Maximize Treatment Rates of OUD in Families

The goal of this project is to demonstrate digital training efficacy at scale and commercial readiness. This pilot project will advance piloted digital training programs for CRAFT and maximize scalab...

New York, NYNA240 participantsWe The Village, Inc.

View Study Details

NCT06106945Recruiting

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma

This is a Phase I/II, modular, open-label, multicenter, dose escalation, and dose expansion/optimization study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and prelimina...

New York, NYPHASE1226 participantsAstraZeneca

View Study Details

NCT07226609Recruiting

A Dietary Study for People With Multiple Myeloma

The purpose of the study is to find out whether a dietary intervention can affect treatment response and/or quality of life for people with newly diagnosed multiple myeloma receiving standard inductio...

New York, NYNA220 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT06679829Recruiting

A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant

The purpose of this study is to see if siltuximab plus population pharmacokinetic (PK)-dosed melphalan works as well as the usual approach (body surface area \[BSA\]-dosed melphalan) in people with mu...

New York, NYPHASE2215 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT06500884Recruiting

A Study to Evaluate Preventive Treatments for Talquetamab-related Oral Toxicity

The purpose of this study is to identify preventive treatments that can minimize the occurrence, severity, and duration of talquetamab-related taste changes (dysgeusia), during the prophylaxis (preven...

New York, NYPHASE2210 participantsJanssen Research & Development, LLC

View Study Details

NCT06055894Recruiting

A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)

The researchers are going this to look at how butyrate levels change in participants' stool after they are on a plant-based diet or dietary supplements (omega-3, curcumin or probiotics) for 2 weeks. A...

New York, NYNA200 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT05737732Recruiting

The Ambient Light Multiple Myeloma Study

The aim of this multi-site randomized control trial will be is to assess the impact Systematic lighting on circadian rhythm entrainment, Inflammation, Neutropenic Fever and Symptom Burden among Multip...

New York, NYNA200 participantsIcahn School of Medicine at Mount Sinai

View Study Details

NCT06934954Recruiting

Early Adolescent Skills for Emotions

The EASE program is an existing, evidence-based program/intervention (originally developed by the WHO), and this study is limited to evaluating the local implementation of this program. The aims of t...

New York, NYNA200 participantsThe New School

View Study Details

NCT06750731Recruiting

Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention

The goal of this observational study is to assess the feasibility and effectiveness of a remote monitoring digital health system on adherence, clinical outcomes, and healthcare utilization in patients...

New York, NY200 participantsMercy Medical Center

View Study Details

NCT06953960Recruiting

A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and change in disease activity o...

New York, NYPHASE1199 participantsAbbVie

View Study Details

NCT06153251Recruiting

A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

The purpose of this study is to assess BMS-986453 in participants with relapsed and/or refractory multiple myeloma (RRMM)....

New York, NYPHASE1187 participantsJuno Therapeutics, Inc., a Bristol-Myers Squibb Company

View Study Details

NCT05640843Recruiting

A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)

The researchers are doing this study to look at how butyrate levels change in participants' stool after they are on a- plant-based diet for at least 12 weeks. All participants will have monoclonal gam...

New York, NYNA180 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT05652335Recruiting

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

The primary purpose of this study is to identify the recommended phase 2 dose (RP2D\[s\]) and schedule(s) to be safe for JNJ-79635322 in Part 1 (dose escalation), and to characterize the safety and to...

New York, NYPHASE1180 participantsJanssen Research & Development, LLC

View Study Details

NCT07116616Recruiting

A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to evaluate the safety and tolerability of mRNA-2808 in participants with relapsed or refractory multiple myeloma (RRMM)....

New York, NYPHASE1166 participantsModernaTX, Inc.

View Study Details

NCT05651932Recruiting

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent...

New York, NYPHASE1165 participantsK36 Therapeutics, Inc.

View Study Details

NCT04844606Recruiting

A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

The main purpose of this study is to evaluate the long-term efficacy of mirikizumab in pediatric participants with ulcerative colitis (UC) or Crohn's disease (CD). The study will last about 172 weeks ...

New York, NYPHASE3150 participantsEli Lilly and Company

View Study Details

NCT06309017Recruiting

Pre-operative Nutrition for Elective Resection Surgery in Inflammatory Bowel Disease

This study aims to determine if improved risk stratification tools and interventions to mitigate malnutrition reduce postoperative risk in patients undergoing elective or emergent resection surgery fo...

New York, NYNA150 participantsNYU Langone Health

View Study Details

NCT05828511Recruiting

A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

This study is researching an experimental drug called linvoseltamab (called "study drug"). The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are eligible for high d...

New York, NYPHASE1149 participantsRegeneron Pharmaceuticals

View Study Details

NCT06896916Recruiting

Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma

Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the adverse events and change in disease ac...

New York, NYPHASE1135 participantsAbbVie

View Study Details

NCT06375044Recruiting

Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma

This is an open-label, multicenter phase 1 clinical trial to evaluate the safety and tolerability, efficacy, and pharmacokinetics of SIM0500 in adult participants with Relapsed or Refractory Multiple ...

New York, NYPHASE1130 participantsJiangsu Simcere Pharmaceutical Co., Ltd.

View Study Details

NCT06140524Recruiting

A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma

This study is researching an investigational drug called linvoseltamab ("study drug") in participants at moderate risk of developing multiple myeloma (about 3 to 10% average annual risk), a group that...

New York, NYPHASE2116 participantsRegeneron Pharmaceuticals

View Study Details

NCT06680037Recruiting

A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders

The main objective of the study is to determine the recommended phase 2 dose (RP2D) of Azercabtagene zapreleucel (azer-cel)....

New York, NYPHASE1100 participantsTG Therapeutics, Inc.

View Study Details

NCT06338150Recruiting

Precision Medicine Study

This will be a 2 year study to evaluate and improve cancer sequencing as applied to the characterization of tumor molecular make-up and the identification of novel therapeutics (total n=100; approxima...

New York, NY100 participantsIcahn School of Medicine at Mount Sinai

View Study Details

NCT06976476Recruiting

Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia

The main purpose of this study is to see if IgPro20 can prevent infection in people with multiple myeloma (MM) who have hypogammaglobulinemia from receiving bispecific monoclonal antibodies (BsAbs)....

New York, NYPHASE2100 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT07284758Recruiting

A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

This is a Phase 2, open-label, single-arm, multicenter study to assess the antimyeloma activity and further characterize the safety, tolerability, PK, and PD of cemsidomide in combination with dexamet...

New York, NYPHASE2100 participantsC4 Therapeutics, Inc.

View Study Details

NCT04879043Recruiting

Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma

This study will assess the safety, tolerability, pharmacokinetics (PK) and the therapeutic potential of HDP-101 in patients with plasma cell disorders including multiple myeloma....

New York, NYPHASE178 participantsHeidelberg Pharma AG

View Study Details

NCT05551793Recruiting

Regeneron AA Multicenter (Dupilumab)

This is a prospective, randomized, double blind, placebo-controlled clinical trial. The study will take place at 4 sites. This trial will enroll a total of 68 patients with moderate to severe AA (affe...

New York, NYPHASE276 participantsEmma Guttman

View Study Details

NCT05932680Recruiting

Limited-duration Teclistamab

This is a single-arm, non-inferiority study in which patients who have achieved a very good partial response (VGPR) or better, according to International Myeloma Working Group (IMWG) response criteria...

New York, NYPHASE275 participantsAbramson Cancer Center at Penn Medicine

View Study Details

NCT07099391Recruiting

A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma

The purpose of this study is to find out whether Tec-RVd (teclistamab, lenalidomide, bortezomib, and dexamethasone) after 3 treatment Cycles of Dara-RVd (daratumumab, lenalidomide, bortezomib, and dex...

New York, NYPHASE165 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT05004987Recruiting

Aβ Dynamics in LLMD

This study will examine the biological factors that may modulate the relationship between depression and the development of Alzheimer's disease (AD). Since the direction of causation between depressio...

New York, NYPHASE460 participantsNYU Langone Health

View Study Details

NCT07149857Recruiting

A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel

The purpose of this study is to evaluate how well (efficacy) cilta-cel works when given with a fludarabine-free lymphodepletion regimen (a process of reducing the number of lymphocytes, a type of whit...

New York, NYPHASE260 participantsJanssen Research & Development, LLC

View Study Details

NCT06747351Recruiting

A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

The main aim of this study is to evaluate the pharmacokinetic (PK) comparability between TAK-881 and HYQVIA subcutaneous (SC) administration for maintenance therapy of CIDP. The participants who are ...

New York, NYPHASE359 participantsTakeda

View Study Details

NCT07304154Recruiting

A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases

This study will have two Phases: Phase 1a and Phase 1b. The goals of this clinical study are to learn more about the study drug KITE-363, by evaluating its safety, tolerability and efficacy in partici...

New York, NYPHASE152 participantsKite, A Gilead Company

View Study Details

NCT06401356Recruiting

An Extension Study for Patients Previously Enrolled in Studies With Pelabresib

The purpose of this study is to evaluate the long-term safety and the clinical benefit of pelabresib in patients with hematological and/or solid tumor indications or advanced malignancies. Additionall...

New York, NYPHASE350 participantsNovartis Pharmaceuticals

View Study Details

NCT05722418Recruiting

CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell maturation antigen (BCMA), to deter...

New York, NYPHASE150 participantsCaribou Biosciences, Inc.

View Study Details

NCT07540221Recruiting

A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

The main goal of the study is to find out whether XEMBIFY, given once a week under the skin, provides similar levels of immunoglobulin G in the blood over time as Gamunex-C, which is given into a vein...

New York, NYPHASE340 participantsGrifols Therapeutics LLC

View Study Details

NCT07073547Recruiting

A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)

This is an interventional, modular, open-label, multicenter study to primarily evaluate the safety and tolerability of AZD0120 in adult participants with multiple myeloma (MM)....

New York, NYPHASE140 participantsAstraZeneca

View Study Details

NCT05787574Recruiting

A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition

The researchers are doing this study to find out whether emapalumab or a combination of fludarabine and dexamethasone are effective in preparing people with a primary immune regulatory disorder (PIRD)...

New York, NYPHASE239 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT05346809Recruiting

Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma

The purpose of this study is to see if Isatuximab can alter the immune system in patients with multiple myeloma or lymphoma upon recovery from the autologous stem cell transplantation. The investigato...

New York, NYPHASE239 participantsDivaya Bhutani

View Study Details

NCT07207200Recruiting

Impact of Morning Light Therapy in IBD

The pilot study will focus on the effects of morning light therapy (MLT) in adult patients with ulcerative colitis (UC) who have evidence of poor sleep quality and active inflammation. The specific po...

New York, NYNA30 participantsIcahn School of Medicine at Mount Sinai

View Study Details

NCT06873815Recruiting

A Study of Fluorescein Sodium in People Undergoing Vulvectomy for Extramammary Paget's Disease (EMPD)

The researchers are doing this study to see if giving people fluorescein sodium as an IV infusion before their vulvectomy for treating extramammary Paget's disease (EMPD) can help surgeons with perfor...

New York, NYPHASE227 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT04614558Recruiting

Isatuximab in Patients With Monoclonal Gammopathy of Renal Significance

The purpose of this study is to see whether Isatuximab can help improve kidney function of participants with MGRS. Isatuximab is approved by the Food and Drug Administration (FDA) for the treatment of...

New York, NYPHASE227 participantsColumbia University

View Study Details

NCT07454382Recruiting

A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma

The purpose of this study is to find out whether the combination of elranatamab and cyclophosphamide is an effective treatment for people with relapsed/refractory multiple myeloma (MM) who have risk f...

New York, NYPHASE226 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT06827860Recruiting

Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse

Induction therapy approaches in recent years have evolved, now utilizing triple or quadruple drug regimens in the majority of patients. By combining anti-CD38 antibodies, proteasome inhibitors (PIs), ...

New York, NYPHASE223 participantsLarysa Sanchez

View Study Details

NCT05642455Recruiting

SPEARHEAD-3 Pediatric Study

This is a pediatric basket study to investigate the safety and efficacy of afamitresgene autoleucel in HLA-A\*02 eligible and MAGE-A4 positive subjects aged 2-17 years of age with advanced cancers....

New York, NYPHASE120 participantsAdaptimmune

View Study Details

NCT06083922Recruiting

A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)

The purpose of this study is to find out whether cyclophosphamide, bortezomib, dexamethasone (CyBorD) with daratumumab SC is a safe treatment combination for MGRS-associated kidney disease including c...

New York, NYPHASE220 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT05040178Recruiting

An Observational Study of Carbaglu® for the Treatment of MMA and PA in Adults and Pediatrics

To obtain short-term and long-term clinical safety information, in pediatric and adult patients with PA and MMA treated with Carbaglu®....

New York, NY20 participantsRECORDATI GROUP

View Study Details

NCT07105059Recruiting

A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma

The researchers are doing this study to find out whether combining teclistamab and mezigdomide is a safe and effective treatment approach in people with relapsed/refractory multiple myeloma (MM)....

New York, NYPHASE118 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT06066346Recruiting

A Study of Talquetamab for People with Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy

The researchers are doing this study to find out whether talquetamab is an effective treatment after BCMA CAR Tcell therapy for people with relapsed or refractory multiple myeloma. All participants in...

New York, NYPHASE217 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT07494019Recruiting

Community Safety and Violence

This study will describe, estimate, and explore the effectiveness of community-centered safety models (CCSMs)-including co-response, alternative response, and community violence intervention modalitie...

New York, NY15 participantsNYU Langone Health

View Study Details

NCT06455280Recruiting

A Study of SIPLIZUMAB in AILD and LT Patients

There is a significant unmet need for safe and effective therapeutic approaches to prevent immune-mediated graft injury and its complications in liver transplant (LT) recipients with autoimmune liver ...

New York, NYPHASE18 participantsElizabeth C. Verna

View Study Details

About Multiple Myeloma Clinical Trials in New York

Multiple myeloma is a cancer of plasma cells in the bone marrow that produce abnormal antibodies. It can cause bone damage, kidney problems, and immune deficiency. Treatments have advanced significantly with proteasome inhibitors, immunomodulatory drugs, and CAR-T cell therapy.

There are currently 76 multiple myeloma clinical trials recruiting participants in New York, NY. These studies are seeking a combined 175,067 participants. Research is being sponsored by NYU Langone Health, UMC Utrecht, Columbia University and 40 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Multiple Myeloma Clinical Trials in New York — FAQ

Are there multiple myeloma clinical trials in New York?

Yes, there are 76 multiple myeloma clinical trials currently recruiting in New York, NY. Browse the studies on this page to find one that fits.

How do I join a clinical trial in New York?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the New York research site will contact you about next steps.

Are clinical trials in New York free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many New York studies also compensate for your time and travel.

What multiple myeloma treatments are being tested?

The 76 active trials in New York are testing new therapies including novel drugs, biologics, and treatment approaches for multiple myeloma.

Data updated July 16, 2026 from ClinicalTrials.gov